Although imatinib may be effective in hypereosinophilic syndromes, the exact response kinetics are not known. Imatinib was administered at 100-400 mg/d each week in a 12-week response-oriented schedule, targeting a complete clinical and haematological remission (CR). CR was achieved in 11/23 patients (6/6 with
A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes / Intermesoli, T., Delaini, F., Acerboni, S., Salmoiraghi, S., Spinelli, O., Guerini, V., Vannucchi, A.m., Mappa, S., Rossi, G., Rossi, V., Di Bona, E., Paratore, S., Carobbio, A., Rambaldi, A., Barbui, T., Bassan, R.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 1365-2141. - 147:5(2009), pp. 681-685. [10.1111/j.1365-2141.2009.07893.x]
A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes
Carobbio A;
2009
Abstract
Although imatinib may be effective in hypereosinophilic syndromes, the exact response kinetics are not known. Imatinib was administered at 100-400 mg/d each week in a 12-week response-oriented schedule, targeting a complete clinical and haematological remission (CR). CR was achieved in 11/23 patients (6/6 with
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
